Table 1. FDA-Approved Rheumatoid Arthritis Indications for Anti-TNF DMARDs Etanercept Infliximab Adalimumab Certolizumab Golimumab Pegol X (1998) X (1999) X (2002) X (2011) X (2011) Moderately to severely active RA Reduction of X (1998) X (1999) X (2002) and symptoms Inhibition of X (2000) X (2000) X (2002) progression of structural damage Improvement X (2003) X (2002) X (2004) in physical function Induction of X (2004) X major clinical response Monotherapy X X X X Combination X X (with X (with MTX X (with MTX) X (with therapy MTX) or other MTX) DMARDs) Use after X X (2004) X X inadequate (inadequate response to > response to 1 DMARDs MTX) Use in X (2000) X (2004; can X (2005; can X patients who be used in be used in patients not patients not have not previously previously previously failed treated with treated with treatment MTX) MTX) with a Use after X inadequate response to > 1 TNF-α antagonists
Table 1. FDA-Approved Rheumatoid Arthritis Indications for Anti-TNF DMARDs Etanercept Infliximab Adalimumab Certolizumab Pegol Golimumab Moderately to severely active RA X (1998) X (1999) X (2002) X (2011) X (2011) Reduction of and symptoms X (1998) X (1999) X (2002) Inhibition of progression of structural damage X (2000) X (2000) X (2002) Improvement in physical function X (2003) X (2002) X (2004) Induction of major clinical response X (2004) X Monotherapy X X X X Combination therapy X X (with MTX) X (with MTX or other DMARDs) X (with MTX) X (with MTX) Use after inadequate response to > 1 DMARDs X (inadequate response to MTX) X (2004) X X Use in patients who have not previously failed treatment with a X (2000) X (2004; can be used in patients not previously treated with MTX) X (2005; can be used in patients not previously treated with MTX) X Use after inadequate response to > 1 TNF-α antagonists X
DMARDs_for_Rheumatoid_Arthritis_Anti_TNF_DMARD_Update.docx